Jarislowsky Fraser Ltd reduced its stake in shares of Sanofi (NYSE:SNY) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,483 shares of the company’s stock after selling 5,686 shares during the quarter. Jarislowsky Fraser Ltd’s holdings in Sanofi were worth $8,488,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its stake in Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after acquiring an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC increased its stake in shares of Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after buying an additional 776 shares in the last quarter. Eagle Ridge Investment Management acquired a new stake in shares of Sanofi in the second quarter valued at $160,000. Bronfman E.L. Rothschild L.P. increased its stake in shares of Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after buying an additional 2,098 shares in the last quarter. Finally, Toronto Dominion Bank increased its stake in shares of Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after buying an additional 180 shares in the last quarter. Hedge funds and other institutional investors own 9.36% of the company’s stock.
Sanofi (NYSE:SNY) opened at $44.56 on Tuesday. The stock has a market capitalization of $113,467.86, a PE ratio of 14.20, a P/E/G ratio of 2.48 and a beta of 0.88. Sanofi has a 1-year low of $38.45 and a 1-year high of $50.65. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26.
WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/11/14/sanofi-sny-holdings-cut-by-jarislowsky-fraser-ltd.html.
SNY has been the subject of a number of research reports. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. BidaskClub lowered Sanofi from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Cowen and Company restated a “market perform” rating and issued a $52.00 target price (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. Finally, Argus restated a “buy” rating and issued a $55.00 target price on shares of Sanofi in a research note on Friday, September 1st. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. Sanofi has a consensus rating of “Hold” and a consensus target price of $53.50.
In other news, major shareholder Sanofi purchased 105,820 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by company insiders.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.